Laatste update :
18/04/2024
Antibioticum   Ceftriaxone disodium  
Injecteerbaar geneesmiddel
Stabiliteit in oplossing Stabiliteit in mengsels Factoren die de stabiliteit beïnvloeden Verenigbaarheden Toedieningswijze Literatuur Pdf
   Molecuulstructuur  

Merknamen in verschillende landen   Merknamen in verschillende landen     

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Acantex Argentinië, Chili
Amcef Mexico
Antibacin Griekenland
Aurofox
Axobat Italië
Azatyl Griekenland
Baktisef Turkije
Biotrakson Polen
Bixon Italië
Bresec Griekenland
Cefaday Turkije
Cefonova Zweden
Cefotrix Denemarken, Duitsland, Oostenrijk
Cefrag Italië
Cephaxon Turkije
Davixon Italië
Daytrix Italië
Deixim Italië
Desefin Turkije
Eftry Italië
Eqicept Turkije
Farcef Griekenland
Fidato Italië
Forsef Turkije
Frineg Italië
Gladius Griekenland
Glorixone Griekenland
Kappacef Italië
Labilex Griekenland
Lendacin Kroatië, Polen, Russisch, Slovenië
Lidacef Kroatië
Mesporin Portugal, Saudi-Arabië
Nevakson Turkije
Nilson Italië
Novocef Turkije
Oframax Texte introuvable (616, ), Polen
Olisef Slovenië
Panatrix Italië
Pantoxon Italië
Ragex Italië
Rocefalin Spanje
Rocefin Brazilië, Italië
Rocephalin Denemarken, Finland, Noorwegen, Zweden
Rocephin Canada, Duitsland, Griekenland, Nederland, Polen, Portugal, Thailand, Turkije, USA, Zuid-Afrika, Zwitserland
Rocephine België, Duitsland, Frankrijk
Sirtap Italië
Tartriakson Polen
Tercefon Oostenrijk
Travilan Griekenland
Unacefin Turkije
Valexime Italië
Literatuur   Injecteerbaar geneesmiddel   Literatuur : Ceftriaxone disodium  
Type Publicatie
3 Artikel Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
11 Artikel Bailey LC, Orosz ST.
Stability of ceftriaxone sodium and metronidazole hydrochloride.
Am J Health-Syst Pharm 1997 ; 54: 424-427.
59 Artikel Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 Artikel Pugh CB, Pabis DJ, Rodriguez C.
Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 123-125.
84 Artikel Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
91 Artikel Lober CA, Dollard PA.
Visual compatibility of gallium nitrate with selected drugs during Y-site injection.
Am J Hosp Pharm 1993 ; 50: 1208-1210.
95 Artikel Pritts D, Hancock D.
Incompatibility of ceftriaxone with vancomycin.
Am J Hosp Pharm 1991 ; 48: 77.
99 Artikel Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
100 Artikel Plumridge RJ, Rieck AM, Annus TP, Langton SR.
Stability of ceftriaxone sodium in polypropylene syringes at -20, 4, and 20°C.
Am J Health-Syst Pharm 1996 ; 43: 2320-2323.
150 Artikel Aujoulat P, Coze C, Braguer D, Raybaud C.
Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.
J Pharm Clin 1993 ; 12: 31-35.
169 Artikel Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Artikel Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
198 Artikel Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
215 Artikel Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426.
241 Artikel Leader WG, Jones JM.
Incompatibility between ceftriaxone sodium and labetolol hydrochloride.
Am J Health-Syst Pharm 1996 ; 53: 2639.
244 Artikel Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Artikel Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Artikel Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Artikel Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Artikel Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
259 Artikel Bailey LC, Tang KT, Medwick T.
Stability of ceftriaxone sodium in infusion-pump syringes.
Am J Hosp Pharm 1993 ; 50: 2092-2094.
275 Artikel Lewis JD, El-Gendy A.
Cephalosporin-pentamidine isethionate incompatibilities.
Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
276 Artikel Parrish MA, Bailey LC, Medwick T.
Stability of ceftriaxone sodium and aminophylline or theophylline in intravenous admixtures.
Am J Hosp Pharm 1994 ; 51: 92-94.
279 Artikel Bailey LC, Cappel KM, Orosz ST.
Stability of ceftriaxone sodium in injectable solutions stored frozen in syringes.
Am J Hosp Pharm 1994 ; 51: 2159-2161.
282 Artikel Rivers TE, Webster AA.
Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags.
Am J Health-Syst Pharm 1995 ; 52: 2568-2570.
299 Artikel Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Artikel Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Artikel Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Artikel Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
315 Artikel Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
317 Artikel Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
335 Artikel Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Artikel Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Artikel Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
432 Artikel Marble DA, Bosso JA, Townsend RJ.
Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions.
Am J Hosp Pharm 1986 ; 43: 1732-1736.
479 Artikel Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
492 Artikel Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Artikel Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
587 Artikel Smith BR.
Effect of storage temperature and time stability of cefmenoxime, ceftriaxone, and cefotetan in 5% dextrose injection.
Am J Hosp Pharm 1983 ; 40: 1024-1025.
589 Artikel Kedzierewicz F, Finance C, Nicolas A, Dixneuf P, Hoffman M.
Stability of parenteral ceftriaxone disodium solutions in frozen and liquid states: effect of freezing and microwave thawing.
J Pharm Sci 1989 ; 78: 73-77.
604 Fabrikant Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
640 Artikel Walker SE, Dranitsaris G.
Stability of reconstituted ceftriaxone in dextrose and saline solutions.
Can J Hosp Pharm 1987 ; 40: 161-166.
649 Artikel Das Gupta V.
Stability of ceftriaxone sodium when mixed with metronidazole injection.
Int J Pharm Compound 1997 ; 1: 280-281.
905 Artikel Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Artikel Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
939 Artikel Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
1135 Artikel Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410 Artikel Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Artikel Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Artikel Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1452 Artikel Muller HJ, Howe K, Frank C, Haker I.
Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*.
Eur Hosp Pharm 2000 ; 6: 17-23.
1508 Artikel Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1611 Artikel Chalmers JR, Bobek MB, Militello MA.
Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.
Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Artikel Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1638 Artikel O'Connell C, Sabra K, Scott K.
Stability of reconstituted ceftriaxone solution in polypropylene syringes.
Eur Hosp Pharm 1996 ; 2: 47-48.
1659 Artikel Xu QA, Trissel LA, Williams KY.
Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics.
J Am Pharm Assoc 2000 ; 40: 509-514.
1674 Artikel Trissel LA, Gilbert DL, Martinez JF.
Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 1515-1522.
1712 Artikel Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Artikel Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Artikel Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1744 Artikel Burkiewicz JS.
Incompatibility of ceftriaxone sodium with lactated Ringer’s injection.
Am J Health-Syst Pharm 1999 ; 56: 384.
1754 Artikel Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1800 Artikel Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803 Artikel Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1840 Artikel Xu QA, Trissel LA, Saenz CA et al.
Stability of three cephalosporin antibiotics in autodose infusion system bags.
J Am Pharm Assoc 2002 ; 42: 428-431.
1847 Artikel Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G.
Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration.
J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1902 Artikel Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925 Artikel Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1937 Artikel Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953 Artikel Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Artikel Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2110 Artikel Hecq JD, Evrard JM, Vanbeckbergen DF, Jamart J, Galanti LM.
Effect of freezing, long term storage and microwave thawing on the stability of ceftriaxone sodium in 5% dextrose infusion polyolefin bags at 2-8°C.
EJHP Science 2006 ; 12, 3: 52-56.
2233 Artikel Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2238 Fabrikant Clinomel - Résumé des caractéristiques du produit
Baxter 2018
2247 Artikel Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2271 Fabrikant Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006
2302 Fabrikant Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium.
Lettre AFFSAPS 30 November 2008 2008 ; 61, 5: 356-357.
3012 Artikel Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3216 Artikel Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3254 Artikel Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408 Artikel Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3520 Fabrikant Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3523 Fabrikant Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Fabrikant Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3549 Fabrikant Amikacine B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3560 Fabrikant Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013
3571 Artikel Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3643 Fabrikant Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3644 Fabrikant Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3674 Fabrikant Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3728 Artikel Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766 Artikel Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Artikel Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3824 Artikel Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3964 Artikel Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3976 Artikel Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055 Artikel Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4144 Artikel Ross A, Boddu S, Mauro V, Churchwell M.
Physical compatibility of milrinone with levofloxacin and ceftriaxone injection.
EJHP 2018 ;75,14:1010-1012
4145 Artikel Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319 Artikel Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4440 Artikel Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4603 Artikel Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4654 Poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021
4693 Artikel Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L.
Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection.
Drug Design Dev Ther 2022 ;16:1433-1440.
4742 Artikel Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales